Quinolines and derivatives
Medchemexpress LLC Apixaban | 503612-47-3 | MFCD11977295 | 99.99% | C25H25N5O4 | 200 MG
Apixaban is a highly selective, reversible, and orally active inhibitor of Factor Xa. It is used in the prevention and treatment of various thromboembolic diseases.
- Highly selective and orally active factor Xa inhibitor
- Reversible factor Xa inhibition
- Ki values of 0.08 nM in human and 0.17 nM in rabbit
- Used for prevention and treatment of thromboembolic disorders
Medchemexpress LLC Sodium dichloroacetate | 2156-56-1 | MFCD00070489 | 99.8% | 150.92 | C2HCl2NaO2 | 200mg
Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na -K -2Cl cotransporter (NKCC) inhibitor Sodium dichloroacetate prevents the phosphorylation of the E1 subunit of PDC promoting the entry of pyruvate into the mitochondria for oxidative metabolism reducing lactate production and simultaneously increasing the production of reactive oxygen species (ROS) Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis Sodium dichloroacetate is promising for research of cancers[1][2]
Medchemexpress LLC 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid | 846549-37-9 | 98.6% | C22H42N4O12 | 1 G
2-((Azido-PEG8-carbamoyl)methoxy)acetic acid is a PEG-based PROTAC linker used in the synthesis of PROTACs. It functions as a click chemistry reagent, featuring an Azide group that facilitates copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with Alkyne-containing molecules. It also participates in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. This product is intended for research use only.
- PEG-based PROTAC linker
- Used in the synthesis of PROTACs
- Click chemistry reagent
- Features an Azide group for CuAAc reactions
- Participates in SPAAC reactions
- Relevant to click chemistry and PROTAC synthesis
- For research use only
Apexbio Technology LLC Meclofenamate Sodium 6385-02-0 200mg
Meclofenamate Sodium (CAS 6385-02-0) is a non-steroidal anti-inflammatory drug (NSAID) that acts by inhibiting cyclooxygenase (COX) enzymes thereby modulating prostaglandin synthesis and attenuating inflammatory signaling Preclinical studies have indicated that Meclofenamate Sodium selectively influences targets involved in lipid metabolism suggesting an expanded role beyond general inflammation suppression Due to its dual inhibitory profile this compound is utilized in biomedical research investigating mechanisms of inflammation as well as in studies focused on metabolic disorders and oncology
Medchemexpress LLC (S,R,S)-AHPC-CO-C9-acid (VH032-NH-CO-C9-acid) | 2172819-78-0 | 95.0% | 628.82 | 25 MG
(S,R,S)-AHPC-CO-C9-acid is an E3 ligase ligand-linker conjugate that can be connected to the ligand for protein to form PROTACs. This product is for research use only and not validated for medical applications.
- E3 ligase ligand-linker conjugate
- Connects to ligand for protein to form PROTACs
- Solid appearance
- White to off-white color
- Store at 4°C, protected from light and under nitrogen
- In solvent, store at -80°C for 6 months, or -20°C for 1 month, protected from light and under nitrogen
- Soluble in DMSO
- Soluble in various in vivo protocols
Medchemexpress LLC 10-Deacetylbaccatin III | 32981-86-5 | 99.79% | 544.59 | 200 MG
10-Deacetylbaccatin III (Standard) is the analytical standard of 10-Deacetylbaccatin III, intended for research and analytical applications. It is commonly used in qualitative, quantitative, and methodological research experiments in HPLC, GC, and MS.
- Grade of analytical standard.
- Reference standard supplied assay.
- Commonly used in HPLC, GC, and MS research experiments.
Apexbio Technology LLC Eltrombopag 496775-61-2 200mg
Eltrombopag is a small molecule orally bioavailable non-peptide agonist targeting the thrombopoietin (TPO) receptor also known as c-Mpl receptor Upon activating this receptor pathway eltrombopag promotes intracellular signaling leading to increased proliferation and differentiation of megakaryocyte progenitor cells thereby stimulating platelet production (thrombopoiesis) In biochemical assays eltrombopag shows potent activity exhibiting an IC50 value of approximately 0 69 M As a research tool this compound is utilized widely in studies investigating mechanisms regulating platelet homeostasis thrombocytopenia-related diseases and efforts to elucidate novel therapeutic strategies targeting hematopoietic lineage differentiation
Apexbio Technology LLC Fludarabine(Synonyms: Fludarabine Phosphate, Fludara, Fludarabinum, 2-Fluoro-ara-AMP, 9H-Purin-6-amine), 200mg, CAS: 21679-14-1.
Fludarabine (CAS 21679-14-1) is a purine analog prodrug that inhibits DNA synthesis Upon cellular uptake it undergoes phosphorylation to its active triphosphate form (F-ara-ATP) disrupting DNA replication through inhibition of critical enzymes such as DNA primase DNA ligase I ribonucleotide reductase and DNA polymerases and In human myeloma RPMI8226 cell assays fludarabine suppressed cell growth reduced Akt phosphorylation and lowered anti-apoptotic proteins XIAP and Survivin In vivo studies demonstrated marked tumor growth inhibition in RPMI8226 xenograft models Fludarabine serves as a tool in oncology research particularly leukemia and multiple myeloma-related studies
Apexbio Technology LLC Pemetrexed 150399-23-8 200mg
Pemetrexed (CAS 150399-23-8) is a folate antagonist that targets multiple enzymes involved in the de novo synthesis of purine and pyrimidine nucleotides including thymidylate synthase (TS) dihydrofolate reductase (DHFR) glycinamide ribonucleotide formyltransferase (GARFT) and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT) Structurally related to the antifolate compound lometrexol Pemetrexed disrupts nucleotide biosynthesis and subsequently inhibits DNA replication in proliferating cells It has demonstrated enzymatic inhibition across several pathways though exhibits limited cytotoxic activity in a range of tumor cell types such as non-small cell lung cancer mesothelioma breast colorectal cervical head and neck and bladder cancers This compound is widely used in preclinical studies of folate pathway inhibition and antimetabolite chemotherapy research
Medchemexpress LLC Argatroban monohydrate | 141396-28-3 | MFCD23102419 | 99.6% | 1 ML
Argatroban monohydrate is a direct, selective thrombin inhibitor. It may also have a complementary effect for preventing thrombus formation without aggravating bleeding tendency due to its monotarget specificity to thrombin.
- Administration (0.5 to 2 micrograms/kg/min) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries.
- Appears to enhance reperfusion with TPA in patients with AMI, particularly in those with delayed presentation, and was associated with lower incidences of major bleeding and adverse clinical outcomes compared to heparin.
- Suitable for creating animal models for thrombolysis.
Medchemexpress LLC Sulfo-SPP | 452072-27-4 | 97.1% | 420.48 g·mol⁻1 | C14H16N2O7S3 | 5 MG
Sulfo-SPP is a heterobifunctional, thiol-cleavable, membrane-impermeable crosslinker used as an ADC linker in bioconjugation research. It reacts selectively with primary amines and contains a cleavable disulfide linkage that enables release under reducing conditions. Supplied for research use only.
- Heterobifunctional thiol-cleavable crosslinker.
- Membrane impermeable sulfonate group improves aqueous solubility.
- Cleavable disulfide linkage for controlled release under reducing conditions.
- Suitable for antibody-drug conjugate and bioconjugation applications.
- Available in small pack sizes for research use.
Apexbio Technology LLC Regorafenib 755037-03-7 200mg
Regorafenib (CAS 755037-03-7) is an orally bioavailable inhibitor targeting multiple receptor tyrosine kinases (RTKs) such as VEGFR1/2/3 PDGFR Kit RET Raf-1 B-RAF and B-RAFV600E By impeding kinase phosphorylation (IC50 values ranging from approximately 1 5 46 nM) regorafenib disrupts signaling pathways associated with angiogenesis tumor cell proliferation and metastasis Preclinically regorafenib inhibited VEGFR2 phosphorylation (IC50 3 nM) and reduced VEGF-induced endothelial cell proliferation in vitro In rodent tumor xenograft models it demonstrated dose-dependent tumor growth suppression and antimetastatic potential supporting its utility for oncology research
Medchemexpress LLC Prucalopride succinate | 179474-85-2 | 99.9% | 200 MG
Prucalopride succinate is an orally active, selective, and specific 5-HT4 receptor agonist. It enhances intestinal motility by promoting intestinal nervous system regeneration and exhibits anticancer activity by blocking the PI3K/AKT/mTor pathway. It is used in studies of chronic constipation, pseudo-intestinal obstruction, and cancer.
- Selective and specific 5-HT4 receptor agonist
- Enhances intestinal motility
- Exhibits anticancer activity
- Induces autophagy and apoptosis in A549/A427 cells
- Promotes regeneration of colonic neural stem cells and neurons
Apexbio Technology LLC TG101209 936091-14-4 200mg
TG101209 (CAS 936091-14-4) is a structurally designed small molecule that functions as a selective inhibitor of Janus kinase 2 (JAK2) It inhibits the JAK/STAT signaling pathway particularly in cell lines harboring JAK2V617F or MPLW515L/K mutations commonly associated with polycythemia vera and primary myelofibrosis respectively In studies using multiple myeloma cell models TG101209 reduces the expression of phosphorylated JAK2 STAT3 and Bcl-xL while inducing overexpression of phosphorylated Erk and Akt This modulation of signaling pathways results in dose- and time-dependent cytotoxicity linked to cell cycle arrest and apoptosis supporting its utility in research on hematological malignancies driven by JAK2 dysregulation
Apexbio Technology LLC Finasteride 98319-26-7 200mg
Finasteride (CAS 98319-26-7) is a small molecule inhibitor of type II 5 -reductase exhibiting an IC of 65 nM By selectively blocking this enzyme finasteride impedes the conversion of testosterone to dihydrotestosterone (DHT) leading to reduced DHT concentrations in prostatic tissue and a subsequent decrease in prostate size in vivo Due to its oral bioavailability and well-characterized mechanism finasteride is widely utilized in research focused on androgen signaling prostatic diseases and the physiological roles of DHT